Genomic Testing in Cancer Market, Global Outlook and Forecast 2022-2028

1 Introduction to Research & Analysis Reports
    1.1 Genomic Testing in Cancer Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Genomic Testing in Cancer Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Genomic Testing in Cancer Overall Market Size
    2.1 Global Genomic Testing in Cancer Market Size: 2022 VS 2028
    2.2 Global Genomic Testing in Cancer Market Size, Prospects & Forecasts: 2022-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Key Genomic Testing in Cancer Players in Global Market
    3.2 Global Companies Genomic Testing in Cancer Product & Technology
4 Players Profiles
    4.1 23andMe
        4.1.1 23andMe Corporate Summary
        4.1.2 23andMe Business Overview
        4.1.3 23andMe Genomic Testing in Cancer Product Offerings & Technology
        4.1.4 23andMe Genomic Testing in Cancer R&D, and Plans
    4.2 Agilent Technologies
        4.2.1 Agilent Technologies Corporate Summary
        4.2.2 Agilent Technologies Business Overview
        4.2.3 Agilent Technologies Genomic Testing in Cancer Product Offerings & Technology
        4.2.4 Agilent Technologies Genomic Testing in Cancer R&D, and Plans
    4.3 Bio-Rad Laboratories
        4.3.1 Bio-Rad Laboratories Corporate Summary
        4.3.2 Bio-Rad Laboratories Business Overview
        4.3.3 Bio-Rad Laboratories Genomic Testing in Cancer Product Offerings & Technology
        4.3.4 Bio-Rad Laboratories Genomic Testing in Cancer R&D, and Plans
    4.4 Centogene
        4.4.1 Centogene Corporate Summary
        4.4.2 Centogene Business Overview
        4.4.3 Centogene Genomic Testing in Cancer Product Offerings & Technology
        4.4.4 Centogene Genomic Testing in Cancer R&D, and Plans
    4.5 Color Genomics
        4.5.1 Color Genomics Corporate Summary
        4.5.2 Color Genomics Business Overview
        4.5.3 Color Genomics Genomic Testing in Cancer Product Offerings & Technology
        4.5.4 Color Genomics Genomic Testing in Cancer R&D, and Plans
    4.6 Gene By Gene
        4.6.1 Gene By Gene Corporate Summary
        4.6.2 Gene By Gene Business Overview
        4.6.3 Gene By Gene Genomic Testing in Cancer Product Offerings & Technology
        4.6.4 Gene By Gene Genomic Testing in Cancer R&D, and Plans
    4.7 Illumina
        4.7.1 Illumina Corporate Summary
        4.7.2 Illumina Business Overview
        4.7.3 Illumina Genomic Testing in Cancer Product Offerings & Technology
        4.7.4 Illumina Genomic Testing in Cancer R&D, and Plans
    4.8 LabCorp
        4.8.1 LabCorp Corporate Summary
        4.8.2 LabCorp Business Overview
        4.8.3 LabCorp Genomic Testing in Cancer Product Offerings & Technology
        4.8.4 LabCorp Genomic Testing in Cancer R&D, and Plans
    4.9 Myriad Genetics
        4.9.1 Myriad Genetics Corporate Summary
        4.9.2 Myriad Genetics Business Overview
        4.9.3 Myriad Genetics Genomic Testing in Cancer Product Offerings & Technology
        4.9.4 Myriad Genetics Genomic Testing in Cancer R&D, and Plans
    4.10 Positive Bioscience
        4.10.1 Positive Bioscience Corporate Summary
        4.10.2 Positive Bioscience Business Overview
        4.10.3 Positive Bioscience Genomic Testing in Cancer Product Offerings & Technology
        4.10.4 Positive Bioscience Genomic Testing in Cancer R&D, and Plans
    4.11 Quest Diagnostics
        4.11.1 Quest Diagnostics Corporate Summary
        4.11.2 Quest Diagnostics Business Overview
        4.11.3 Quest Diagnostics Genomic Testing in Cancer Product Offerings & Technology
        4.11.4 Quest Diagnostics Genomic Testing in Cancer R&D, and Plans
    4.12 Thermo Fisher Scientific
        4.12.1 Thermo Fisher Scientific Corporate Summary
        4.12.2 Thermo Fisher Scientific Business Overview
        4.12.3 Thermo Fisher Scientific Genomic Testing in Cancer Product Offerings & Technology
        4.12.4 Thermo Fisher Scientific Genomic Testing in Cancer R&D, and Plans
5 Sights by Region
    5.1 By Region - Global Genomic Testing in Cancer Market Size, 2023 & 2028
    5.2 By Region - Global Genomic Testing in Cancer Revenue, (2023-2028)
    5.3 United States
        5.3.1 Key Players of Genomic Testing in Cancer in United States
        5.3.2 United States Genomic Testing in Cancer Development Current Situation and Forecast
    5.4 Europe
        5.4.1 Key Players of Genomic Testing in Cancer in Europe
        5.4.2 Europe Genomic Testing in Cancer Development Current Situation and Forecast
    5.5 China
        5.5.1 Key Players of Genomic Testing in Cancer in China
        5.5.2 China Genomic Testing in Cancer Development Current Situation and Forecast
    5.6 Rest of World
6 Sights by Product
    6.1 by Type - Global Genomic Testing in Cancer Market Size Markets, 2023 & 2028
    6.2 Breast Cancer
    6.3 Lung Cancer
    6.4 Blood Cancer
    6.5 Liver Cancer
    6.6 Stomach Cancer
    6.7 Others
7 Sights by Application
    7.1 By Application - Global Genomic Testing in Cancer Market Size, 2023 & 2028
    7.2 General Hospitals
    7.3 Specialty Clinics
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer